journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/28416151/american-association-for-cancer-research-annual-meeting-2017
#1
Alexandra Sklan
No abstract text is available yet for this article.
April 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28416150/stem-cell-transplantation-in-multiple-myeloma
#2
Manjulika Das
No abstract text is available yet for this article.
April 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28416149/escalated-anthracycline-dose-in-adult-aml
#3
Vijay Shankar Balakrishnan
No abstract text is available yet for this article.
April 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28410997/international-incidence-of-childhood-cancer-2001-10-a-population-based-registry-study
#4
Eva Steliarova-Foucher, Murielle Colombet, Lynn A G Ries, Florencia Moreno, Anastasia Dolya, Freddie Bray, Peter Hesseling, Hee Young Shin, Charles A Stiller
BACKGROUND: Cancer is a major cause of death in children worldwide, and the recorded incidence tends to increase with time. Internationally comparable data on childhood cancer incidence in the past two decades are scarce. This study aimed to provide internationally comparable local data on the incidence of childhood cancer to promote research of causes and implementation of childhood cancer control. METHODS: This population-based registry study, devised by the International Agency for Research on Cancer in collaboration with the International Association of Cancer Registries, collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 20 years in populations covered by high-quality cancer registries with complete data for 2001-10...
April 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28408286/carcinogenicity-of-welding-molybdenum-trioxide-and-indium-tin-oxide
#5
Neela Guha, Dana Loomis, Kathryn Z Guyton, Yann Grosse, Fatiha El Ghissassi, Véronique Bouvard, Lamia Benbrahim-Tallaa, Nadia Vilahur, Karen Muller, Kurt Straif
No abstract text is available yet for this article.
April 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28395881/adopting-a-new-stance-on-immunotherapy-for-uveal-melanoma
#6
Kimberly M Komatsubara, Richard D Carvajal
No abstract text is available yet for this article.
April 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28395880/treatment-of-metastatic-uveal-melanoma-with-adoptive-transfer-of-tumour-infiltrating-lymphocytes-a-single-centre-two-stage-single-arm-phase-2-study
#7
Smita S Chandran, Robert P T Somerville, James C Yang, Richard M Sherry, Christopher A Klebanoff, Stephanie L Goff, John R Wunderlich, David N Danforth, Daniel Zlott, Biman C Paria, Arvind C Sabesan, Abhishek K Srivastava, Liqiang Xi, Trinh H Pham, Mark Raffeld, Donald E White, Mary Ann Toomey, Steven A Rosenberg, Udai S Kammula
BACKGROUND: Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have shown efficacy in metastatic cutaneous melanoma, their use in ocular variants has been disappointing. Recently, adoptive T-cell therapy has shown salvage responses in multiple refractory solid tumours. Thus, we sought to determine if adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs) could mediate regression of metastatic uveal melanoma...
April 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28392203/laparoscopic-and-abdominal-hysterectomy-are-equivalent
#8
Talha Khan Burki
No abstract text is available yet for this article.
April 6, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28392202/accidental-hpv-vaccination-in-pregnancy-no-adverse-effects
#9
Vijay Shankar Balakrishnan
No abstract text is available yet for this article.
April 6, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28392201/ongoing-drugs-shortage-in-venezuela-and-effects-on-cancer-care
#10
Talha Khan Burki
No abstract text is available yet for this article.
April 6, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28389317/chemotherapy-for-advanced-urothelial-cancer-end-of-the-beginning
#11
Robert Dreicer
No abstract text is available yet for this article.
April 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28389316/maintenance-therapy-with-vinflunine-plus-best-supportive-care-versus-best-supportive-care-alone-in-patients-with-advanced-urothelial-carcinoma-with-a-response-after-first-line-chemotherapy-maja-sogug-2011-02-a-multicentre-randomised-controlled-open-label-phase
#12
Jesus García-Donas, Albert Font, Begoña Pérez-Valderrama, José Antonio Virizuela, Miquel Ángel Climent, Susana Hernando-Polo, José Ángel Arranz, Maria Del Mar Llorente, Nuria Lainez, José Carlos Villa-Guzmán, Begoña Mellado, Aránzazu González Del Alba, Daniel Castellano, Enrique Gallardo, Urbano Anido, Xavier García Del Muro, Montserrat Domènech, Javier Puente, Rafael Morales-Barrera, Jose Luis Pérez-Gracia, Joaquim Bellmunt
BACKGROUND: Maintenance therapy improves outcomes in various tumour types, but cumulative toxic effects limit the choice of drugs. We investigated whether maintenance therapy with vinflunine would delay disease progression in patients with advanced urothelial carcinoma who had achieved disease control with first-line chemotherapy. METHODS: We did a randomised, controlled, open-label, phase 2 trial in 21 Spanish hospitals. Eligible patients had locally advanced, surgically unresectable, or metastatic transitional-cell carcinoma of the urothelial tract, adequate organ function, and disease control after four to six cycles of cisplatin and gemcitabine (carboplatin allowed after cycle four)...
April 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28373007/avelumab-for-metastatic-or-locally-advanced-previously-treated-solid-tumours-javelin-solid-tumor-a-phase-1a-multicohort-dose-escalation-trial
#13
Christopher R Heery, Geraldine O'Sullivan-Coyne, Ravi A Madan, Lisa Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L Marté, Lauren M Lepone, Renee N Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin Chin, Jeffrey Schlom, James L Gulley
BACKGROUND: Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting its binding to PD-1, which inactivates T cells. We aimed to establish the safety and pharmacokinetics of avelumab in patients with solid tumours while assessing biological correlatives for future development. METHODS: This open-label, single-centre, phase 1a, dose-escalation trial (part of the JAVELIN Solid Tumor trial) assessed four doses of avelumab (1 mg/kg, 3 mg/kg, 10 mg/kg, and 20 mg/kg), with dose-level cohort expansions to provide additional safety, pharmacokinetics, and target occupancy data...
March 31, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28373006/avelumab-an-anti-pd-l1-monoclonal-antibody-shows-activity-in-various-tumour-types
#14
Athanasios Kotsakis, Vassilis Georgoulias
No abstract text is available yet for this article.
March 31, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28373005/avelumab-for-patients-with-previously-treated-metastatic-or-recurrent-non-small-cell-lung-cancer-javelin-solid-tumor-dose-expansion-cohort-of-a-multicentre-open-label-phase-1b-trial
#15
James L Gulley, Arun Rajan, David R Spigel, Nicholas Iannotti, Jason Chandler, Deborah J L Wong, Joseph Leach, W Jeff Edenfield, Ding Wang, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, Jean-Marie Cuillerot, Karen Kelly
BACKGROUND: Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this dose-expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC). METHODS: In this dose-expansion cohort of a multicentre, open-label, phase 1 study, patients with progressive or platinum-resistant metastatic or recurrent NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the USA...
March 31, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28366275/quality-of-life-after-treatments-for-prostate-cancer
#16
Priya Venkatesan
No abstract text is available yet for this article.
March 30, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28366274/pembrolizumab-in-advanced-head-and-neck-cancer
#17
Vicki Brower
No abstract text is available yet for this article.
March 30, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28359785/optimum-dosing-of-ipilimumab-in-melanoma-too-little-too-late
#18
Alexander M Menzies, Georgina V Long
No abstract text is available yet for this article.
March 27, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28359784/ipilimumab-10-mg-kg-versus-ipilimumab-3-mg-kg-in-patients-with-unresectable-or-metastatic-melanoma-a-randomised-double-blind-multicentre-phase-3-trial
#19
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Mackiewicz, Vanna Chiarion-Sileni, Ana Arance, Céleste Lebbé, Lars Bastholt, Omid Hamid, Piotr Rutkowski, Catriona McNeil, Claus Garbe, Carmen Loquai, Brigitte Dreno, Luc Thomas, Jean-Jacques Grob, Gabriella Liszkay, Marta Nyakas, Ralf Gutzmer, Joanna Pikiel, Florent Grange, Christoph Hoeller, Virginia Ferraresi, Michael Smylie, Dirk Schadendorf, Laurent Mortier, Inge Marie Svane, Delphine Hennicken, Anila Qureshi, Michele Maio
BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg. METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses...
March 27, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28343979/proposed-us-government-budget-cuts-would-devastate-cancer-research
#20
Bryant Furlow
No abstract text is available yet for this article.
March 23, 2017: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"